Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.
Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. Within transfusion technology, Fresenius Kabi offers products used in the collection and processing of blood and cell components, as well as in transfusion medicine and cell therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
Fresenius Kabi employs over 40,000 people worldwide. In 2021 the company reported sales of more than €7 billion. Fresenius Kabi AG is a wholly owned subsidiary of the Fresenius SE & Co. KGaA health care group.
Key figures (IFRS)
|€ in milions||2021||2020||Growth|
|7,193||6,976||+ 4 %|
|1,153||1,095||+ 7 %|
|778||730||+ 8 %|
Operating cash flow
|1,203||1,143||+ 5 %|
|533||718||- 26 %|
R & D expenses
|595||553||+ 8 %|
Employees (December 31)
|41,397||40,519||+ 2 %|
- Some figures adjusted for special items
- Net income = Net income attributable to shareholders of Fresenius Kabi